While AbbVie ($ABBV) is widely expected to be the second entrant to the soon-to-explode market for hepatitis C cocktail drugs after standard-bearer Gilead Sciences ...
This dynamic duo appears to be on track to give Gilead's portfolio of hepatitis C products a run for its money. Aside from being a dominant player in HIV therapeutics, Gilead has really left a mark in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback